Justine Cohen, DO

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 2 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 1 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

Drs Justine Cohen and Brent Moody provide their key takeaways and panel discussion highlights related to the management of patients with basal cell carcinoma.

An expert in dermatology shares her insights into the duration of treatment and dose adjustments for systemic treatments in patients with basal cell carcinoma.

Dr Justine Cohen discusses her approach to systemic treatment selection in her patients with basal cell carcinoma; highlighting the importance of individualizing the treatment plan.

Justine Cohen, DO and Brent Moody M.D., F.A.C.P., F.A.A.D, comment on which patients would be appropriate for non-surgical treatment options in the management of their basal cell carcinoma.